Pages

Thursday, August 11, 2011

PT Kalbe Farma Tbk - Build A New Plant

PT Kalbe Farma Tbk (KLBF) more agressive to expand. This pharmaceutical Issuer intends to build a new factory in the Delta region Sillicon, Cikarang, West Java. The factory is specialized in producing OTC, such as ulcer drug, the plan was built early 2012.

Director KLBF, Vidjongtius say, a factory area is approximately 5,000 square meters (m2) to 6,000 m2. The investment value of the plant is estimated at Rp 100 billion to Rp 150 billion.

Source of funds entirely from internal cash this company. KLBF does not need a loan from a third party to finance the expansion of its production. Understandably, the current internal cash KLBF fairly large, Rp 2 trillion. "Our debt is small, about Rp 160 billion. That, too, for working capital," he said, in Jakarta, Tuesday (9 / 8).

Construction of the plant was a continuation of the company's production expansion program. This year, KLBF has built two new factories. Each is a generic drug manufacturer located in Cikarang and cancer drug factory in Pulogadung, East Jakarta. The factory in Cikarang is ready to operate, and are just waiting permission Agency for Drugs and Drink (BPOM) are expected to fall within the next two months.

Currently, the development of cancer drugs factory in Pulogadung still ongoing. The factory covering an area of ​​3000-4000 m 2 was estimated to larger investments, approximately USD 200 billion. The plant is scheduled to operate the cancer drug later this year.

In addition to aggressively build the plant in the country, KLBF also intend taking square off to build a plant in some countries especially the Philippines, Vietnam and Thailand because they have a prospective market in KLBF.

Philippines for instance, is already a market for products KLBF the Extra Joss. Until the first half of 2011, KLBF already achieved sales of Extra Joss in there worth U.S. $ 5 million, higher than last year, about U.S. $ 3 million-US $ 4 million. Construction of the plant can be an investment of U.S. $ 5 million.

No comments:

Post a Comment